Screener
Janux Therapeutics JANX Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Janux Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The source filing: Janux Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:18 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338078
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Purchases of property and equipment | (475) | (844) |
| Purchases of short-term investments | (257,593) | (463,976) |
| Maturities of short-term investments | 227,570 | 125,990 |
| Net cash used in investing activities | (30,498) | (338,830) |
| Cash flows from financing activities | ||
| Proceeds from exercise of common stock options and employee stock purchase plan | 5,785 | 1,855 |
| Payments of issuance costs | — | (347) |
| Net cash provided by financing activities | 5,785 | 1,508 |
Item 1. Financial Statements.
FAQ
- What is Janux Therapeutics's investing cash flow?
- Janux Therapeutics (JANX) reported investing cash flow of -$38.78M in Q2 2026.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.
Ask your AI about Janux Therapeutics's investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude